ArticleHeliyon2024
Prognostic value of visceral protein ratios in patients with colon cancer.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess different combinations of visceral proteins and to elucidate their value in predicting progression-free survival (PFS) and overall survival (OS) in patients with colon cancer. The visceral protein ratios included the albumin-globulin ratio (AGR), prealbumin-globulin ratio (PGR), and albumin-prealbumin-globulin ratio (APGR). Compared with AGR and PGR, APGR had the best time-dependent area under the receiver operating characteristic curves for predicting the outcomes. High AGR/PGR/APGR levels were associated with an increased risk of mortality. High AGR (HR = 0.816, 95%CI: 0.719-0.925, p = 0.001), PGR (HR = 0.831, 95%CI: 0.724-0.953, p = 0.008), and APGR (HR = 0.789, 95%CI: 0.688-0.904, p < 0.001) were independent risk factors for PFS. For every SD increase in AGR, PGR, and APGR, the risk of poor OS in patients with colon cancer was reduced by 16.9 % (HR = 0.831, 95%CI, 0.733-0.943; p = 0.001), 15.1 % (HR = 0.849, 95%CI, 0.739-0.976; p = 0.021), and 19.1 % (HR = 0.809, 95%CI, 0.705-0.928; p = 0.002), respectively. Logistic regression models showed that AGR, PGR, and APGR were independent factors that affected recurrence. Visceral protein ratios are independent predictors of PFS and OS. Compared to the existing visceral protein ratios (AGR and PGR), APGR is a more accurate and sensitive indicator for predicting the outcomes of patients with colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.